As filed with the Securities and Exchange Commission on March 10, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Satsuma Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
2834
|
|
81-3039831
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Primary Standard Industrial
Classification Code Number)
|
|
(I.R.S. Employer
Identification Number)
|
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(650) 410-3200
(Address, including zip code, and telephone number, including area code, of Registrants principal executive offices)
2016 Equity Incentive Plan,
2019 Incentive Award Plan,
2019 Employee Stock Purchase Plan
(Full Title of the Plan)
John Kollins
President
and Chief Executive Officer
Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(650) 410-3200
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
|
|
Brian J. Cuneo
Alan C. Mendelson
Miles
P. Jennings
Latham & Watkins LLP
140 Scott Drive
Menlo
Park, California 94025
Telephone: (650) 328-4600
|
|
Tom ONeil
Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
Telephone: (650) 410-3200
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company,
and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Each Class of Securities
to be Registered
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering Price
Per Share(2)
|
|
Proposed
Maximum
Aggregate Offering
Price Per Share
|
|
Amount of
Registration Fee
|
Common Stock, $0.0001 par value per share
|
|
695,281(3)
|
|
$26.42
|
|
$18,369,324.02
|
|
$2,384.34
|
Common Stock, $0.0001 par value per share
|
|
173,820(4)
|
|
$26.42
|
|
$4,592,324.40
|
|
$596.09
|
Total:
|
|
869,101
|
|
$26.42
|
|
$22,961,648.42
|
|
$2,980.43
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this
registration statement shall also cover any additional shares of the Registrants common stock that become issuable under the 2019 Incentive Award Plan (the 2019 Plan) and the 2019 Employee Stock Purchase Plan (the ESPP)
by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrants receipt of consideration which would increase the number of outstanding shares of common stock.
|
(2)
|
This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of
calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrants common stock as reported on The Nasdaq Global Market on
March 9, 2020, which is $26.42.
|
(3)
|
Represents the additional shares of common stock available for future issuance under the 2019 Plan resulting
from an annual increase as of January 1, 2020.
|
(4)
|
Represents the additional shares of common stock available for future issuance under the ESPP resulting from an
annual increase as of January 1, 2020.
|
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.